Slide 1Oral Colorectal Presentations: Discussion Abstracts #4009 - #4011 Cathy Eng, M.D. The University of Texas M.D. Anderson Cancer Center May 31, 2008 Slide 2 Disclosures:…

MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% 23 % risk reduction…

MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% 23 % risk reduction…

A Report from ASCO 2007 First-Line Metastatic Colorectal Cancer Edward Chu, MD Professor, Medicine & Pharmacology Chief, Section of Medical Oncology Deputy Director,…

Slide 1 www.OncologyEducation.ca KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without…